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Subjectively, all three patients reported marked improve-
ment in their quality of life with no significant side effects
reported. The average daily duration of the patient’s epistaxis
reduced from baseline of 35 (19) to 4 (2) min within
3 months of starting treatment.
Following treatment, the nasal mucosa of all three patients
became less vascular and pale on nasendoscopy. The average
total number of pulsed laser dye cautery treatments applied
to each patient in the 6 months before treatment was 238
(100) and this was 246 (30) in the 6 months following
initiation of treatment. Therefore, no significant change in
the requirement for cautery was found.
Whilst two of the patients had previously received blood
transfusions for symptomatic anaemia, none of the patients
required any blood products during the study or within
6 months of initiating treatment. The only patient requiring
regular parenteral iron was the 67-year-old male on dual
anti-platelet therapy. As a result of recurrent symptomatic
anaemia due to iron-deficiency, he had required monthly
intravenous iron support for over 3 years. Four months after
starting treatment, the reduction in his epistaxis allowed him
to omit his usual iron infusions for the following 7 months.
In conclusion, bevacizumab can be applied safely as a
nasal spray to patients with HHT to produce a sustained
reduction in epistaxis severity. The fact that no reduction in
the requirement for laser cautery was identified may indicate
that bevacizumab acts to reduce the propensity of the
telangectasia to bleed rather than reducing their number. The
current NHS cost for 100 mg of bevacizumab administered
topically is £24266, significantly lower than the 5–10 mg/kg
doses used for intravenous administration in some (Bose
et al, 2009) but not all reports (Patrizia et al, 2011). The sus-
tained response reported here suggests that this treatment
may offer a significant financial benefit in patients that are
dependent upon regular blood products (a unit of red cells
currently costs £123 in the United Kingdom) or intravenous
iron support (costs dependent on dose and preparation used,
but range between £80 and £170 based upon 1000 mg dose).
Further studies are required to optimize the dose intensity
and to determine the duration of response.
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Ponatinib in patients with refractory acute myeloid leukaemia:
findings from a phase 1 study
Activating mutations in the FMS-like tyrosine kinase-3
(FLT3), a tyrosine kinase receptor important in haematopoi-
esis, are among the most common molecular aberrations in
acute myeloid leukaemia (AML), occurring in 30% of adult
patients (Levis & Small, 2003). Common FLT3-activating
mutations include FLT3 internal tandem duplications
(FLT3-ITDs), detected in about 23% of AML patients, and
point mutations within the tyrosine kinase domain, found in
about 8% (Levis & Small, 2003). These mutations result in a
constitutively active FLT3 receptor, leading to growth factor–
independent proliferation and survival of leukaemic cells and
conferring poor prognosis (Levis & Small, 2003).
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Clinical studies of single-agent first-generation FLT3 inhibi-
tors have demonstrated clinical activity, with responses that are
typically short-lived and mostly partial or complete responses
with incomplete haematopoietic recovery. This may be due to
suboptimal potency and/or pharmacokinetics, leading to insuf-
ficient or transient target inhibition, or concomitant c-kit
inhibition (Knapper, 2011). Recently, high potency second-
generation FLT3 inhibitors (e.g., quizartinib) have shown
substantial efficacy as monotherapy, suggesting a potency
threshold for clinical benefit (Knapper, 2011). The validation
of FLT3-ITD as a therapeutic target has rekindled interest in
developing and testing new potent FLT3 inhibitors in AML
patients with FLT3-ITD mutations (Smith et al, 2012).
Ponatinib is a novel, orally administered tyrosine kinase
inhibitor (TKI) and a potent pan–BCR-ABL1 inhibitor
(O’Hare et al, 2009). Based on results in patients with chronic
myeloid leukaemia (CML) and Philadelphia chromosome–
positive acute lymphoblastic leukaemia (Ph+ ALL) in phase 1
and phase 2 clinical trials (Cortes et al, 2012a,b), ponatinib
(45 mg once daily) has been approved in the United States for
the treatment of patients with CML and Ph+ ALL that is resis-
tant or intolerant to prior TKI therapy. Preclinical studies
revealed that ponatinib also potently inhibits FLT3, leading to
apoptosis of leukaemic cell lines carrying the FLT3-ITD muta-
tion and tumour regression in xenograft models, suggesting
the potential for activity in patients with AML (Gozgit et al,
2011). Additionally, ponatinib appears to retain activity
against the clinically-relevant quizartinib-resistant mutant
FLT3-ITD F691L (Smith et al, 2013). Here we report the first
clinical experience with ponatinib in 12 AML patients
included in the phase 1 study (Methods S1).
The median age of these patients was 49 (30–72) years.
The median time from diagnosis to treatment was 1 year.
Patients received a median of 3 (1–7) prior therapies; 58%
had received three or more prior therapies (Table I and
Table S1). Mutational analysis in a central laboratory con-
firmed the presence of FLT3-ITD in seven patients (58%).
Three additional patients did not have an adequate DNA
sample at study entry; however, they had a history of
FLT3-ITD mutation – as reported by the investigator – and
they are included in the FLT3-ITD mutation–positive group
for these analyses. Three patients (all FLT3-ITD mutation
positive) were previously treated with one or more FLT3
inhibitors (sorafenib, quizartinib, and/or IMC-EB10); one
patient progressed on IMC-EB10 and had a partial response
to sorafenib, one patient had a complete response to sorafe-
nib and a partial response to quizartinib, and one patient
had a partial response to quizartinib. Seven patients (70%)
with FLT3-ITD mutation were FLT3 inhibitor–na€ıve
(Table I). The median treatment duration was
52 (10–173) d. At the time of analysis, all patients had dis-
continued ponatinib: 5 (42%) due to death (all unrelated to
ponatinib), 3 (25%) due to adverse events [AEs: unrelated
central nervous system (CNS) haemorrhage, possibly related
acute pancreatitis, unrelated graft versus host disease],
2 (17%) due to progressive disease (PD), and 2 (17%) due
to investigator decision (Table I).
Nine patients experienced at least one treatment-related AE.
The most common treatment-related AEs occurring in two or
more patients were pancreatitis (n = 3) and petechiae (n = 2).
Three patients experienced a treatment-related serious AE
(SAE) of pancreatitis (all grade 2), which was a dose-limiting
toxicity in this trial (Cortes et al, 2012a). Pancreatitis resolved
in two patients after dose interruption, lasting 3 d in one
patient and 8 d in the other. These two patients continued
therapy at a reduced dose (30 mg) and were subsequently re-
escalated to 45 mg without recurrence. The third patient dis-
continued therapy per investigator decision. Additional details
regarding treatment-emergent AEs and SAEs can be found in
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Fig 1. Course of the disease in three responders during ponatinib
treatment. (A) Patient 6, who achieved partial remission. (B) Patient
8, who achieved complete remission with incomplete blood count
recovery. (C) Patient 12, who achieved complete remission with
incomplete blood count recovery. PB, peripheral blood; BM, bone
marrow; ANC, absolute neutrophil count.
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Table S2. Seven patients died during the study for reasons not
related to ponatinib: disease progression (n = 3), multiorgan
failure (n = 2), pneumonia and sepsis (n = 1), and CNS
haemorrhage (n = 1; Table I). Ponatinib had an acceptable
safety profile in this small group of patients with refractory
AML, similar to that observed in patients with CML and Ph+
ALL. Few treatment-related AEs were reported; the most com-
mon was pancreatitis, which was manageable, and re-challenge
with ponatinib was possible in most cases.
The geometric mean maximal concentration and area
under the curve of single-dose ponatinib at day 1, cycle 1 in
AML patients were 97 and 1441 nmol/l h, respectively,
similar to findings across all 31 patients receiving 45 mg
ponatinib (988 and 13601 nmol/l h).
The overall response rate (RR, partial remission or better)
was 3/12 (25%): 2 patients achieved complete remission with
incomplete blood count recovery and one patient
experienced partial remission (Table I, Fig 1). These three
responders carried FLT3-ITD mutations and were all FLT3
inhibitor–na€ıve; the duration of ponatinib treatment in these
patients was 3–6 months. Among 10 patients with FLT3-ITD
mutations, RR was 3/10 (30%). Among seven patients with
FLT3-ITD mutations who were FLT3 inhibitor–na€ıve, RR
was 3/7 (43%). Three patients (2 FLT3-ITD negative) had
stable disease, as they did not meet criteria for complete/par-
tial remission or PD; however, peripheral blood blasts in two
of these patients decreased considerably (~60–90%) during
the first treatment cycle. The RR reported with quizartinib in
phase 1 testing was 30% (Cortes et al, 2009) and 10% with
sorafenib (Borthakur et al, 2011). Although the sample size
reported here is small, these results suggest that ponatinib
has clinical activity in AML patients with FLT3-ITD, requir-
ing confirmation in a larger cohort of patients and with
additional focus on optimization of response (e.g., combina-
tion therapy) and response durability.
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Cyclosporin combined with levamisole for refractory or
relapsed severe aplastic anaemia
About one-third of patients with severe aplastic anaemia (SAA)
are refractory or relapse after treatment with immunosuppres-
sive therapy (IST) by anti-thymocyte globulin (ATG) plus cy-
closporin (CSA; Olnes et al, 2012). Allogeneic haematopoietic
stem-cell transplantation (HSCT) could be effective as salvage
therapy, but it is difficult to find a suitable donor, limited by
the family planning policy in China. Intensification of current
IST regimen seems to hit the ceiling (Passweg & Tichelli, 2009).
However, patients in developing countries cannot afford the
repeated courses of ATG due to the high-costs burden.
A novel IST regimen with a practicable and economical
solution would be ideal. Levamisole (LMS), which had been
originally designed for anthelminthic applications, has a
broad range of immunomodulatory effects (Stevenson et al,
Correspondence
ª 2013 John Wiley & Sons Ltd552
British Journal of Haematology, 2013, 162, 547–569
